At Ichnos Sciences, we’re working to make real progress in science and medicine. Explore our recent publications to discover how we’re shifting medicine forward.
|04/27/2017||BEAT® Antibody Engineering Platform||Immunoglobulin domain interface exchange as a platform technology for the generation of Fc heterodimers and bispecific antibodies||Skegro D. et al.||Journal of Biological Chemistry|
|02/06/2019||ISB 830||GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis||Guttman-Yassky E. et al.||Journal of Allergy and Clinical Immunology|
|09/12/2019||BEAT® Antibody Engineering Platform||Single-step Protein A and Protein G avidity purification methods to support bispecific antibody discovery and development||Ollier R. et al.||mAbs|
|05/13/2020||BEAT® Antibody Engineering Platform||A single mutation increases heavy-chain heterodimer assembly of bispecific antibodies by inducing structural disorder in one homodimer species||Stutz C. et al.||Journal of Biological Chemistry|
|01/28/2021||Cell Line Development||Generation of homogeneous cell populations with tunable levels of transgene expression||Schlicht D. et al.||Journal of Biotechnology|
|05/03/2021||ISB 830||Telazorlimab in Atopic Dermatitis: Phase 2b Study Shows Improvement at 16 Weeks||Sher, L.||2021 Society for Investigative Dermatology Virtual Meeting|
|06/04/2021||ISB 1342||ISB 1342: A First-In-Class CD38 T Cell Engager for the Treatment of Relapsed Refractory Multiple Myeloma||Doucey, M.||2021 ASCO Annual Meeting|
|11/04/2021||ISB 1442||ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of Relapsed Refractory Multiple Myeloma||Sammicheli S. et al.||American Society of Hematology Annual Meeting|
|12/10/2021||ISB 1442||Preclinical Data Summary: First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for Relapsed / Refractory Multiple Myeloma||Sammicheli S. et al.||Presentation at the American Society of Hematology Annual Meeting|
|04/13/2022||ISB 1442||ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of CD38+ Malignancies||Sammicheli S. et al.||American Association for Cancer Research Annual Meeting|
The link above is provided for your convenience, and Ichnos is not responsible for content, privacy, or security issues associated with your visit to external websites.
Note: Assets that were previously identified as GBR XXXX are now identified as ISB XXXX.